The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate.The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87)
For help understanding what genuine semaglutide looks like, check our guide on what color semaglutide should be
Information provided is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
Biomarkers that could identify metabolic disturbances and NAFLD early, as well as supportive therapies, could be beneficial, and to that end I reviewed two current articles: Mardinoglu, M., et